Literature DB >> 28040851

Impact of laser pulse duration on the reduction of intraocular pressure during selective laser trabeculoplasty.

Spela Stunf Pukl1, Brigita Drnovšek-Olup2.   

Abstract

PURPOSE: To evaluate the efficacy of selective laser trabeculoplasty (SLT) to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG), normal tension glaucoma (NTG) or ocular hypertension (OHT), when performed with laser pulse duration of 1 ns compared with standard 3-5 ns.
METHODS: Bilateral SLT with a 532 nm Q-switched neodymium-doped yttrium aluminium garnet laser was conducted in 30 patients (60 eyes) with POAG (n = 5), NTG (n = 2) or OHT (n = 23). Pulse duration was 1 ns in the right eye (30 eyes; cases) and 3-5 ns in all left eyes (controls). Main outcome measures were IOP at 1 h, 1 day, 8 weeks and 6 months, and the rate of adverse ocular tissue reactions in all eyes.
RESULTS: Mean 1 ns and 3-5 ns SLT IOPs were 24.1 and 24.3 mmHg, respectively, at baseline. No statistically significant difference in mean 1 ns and 3-5 ns SLT IOP was observed at 1 h (P = 0.761), 1 day (P = 0.758), 8 weeks (P = 0.352) and 6 months postoperatively (P = 0.879). No significant difference in postoperative anterior chamber inflammation was observed between the eyes (P = 0.529). Treatment with both laser pulse durations resulted in minor ultrastructural changes in the drainage angle.
CONCLUSIONS: SLT performed with a 1 ns laser pulse duration does not appear to be inferior to SLT performed with the standard 3-5 ns duration at lowering IOP in treatment-naïve patients with POAG, NTG or OHT.

Entities:  

Keywords:  Intraocular pressure; Q-switched lasers; Trabeculoplasty

Mesh:

Year:  2016        PMID: 28040851     DOI: 10.1007/s10792-016-0426-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  23 in total

1.  > 6 MW peak power at 532 nm from passively Q-switched Nd:YAG/Cr4+:YAG microchip laser.

Authors:  Rakesh Bhandari; Takunori Taira
Journal:  Opt Express       Date:  2011-09-26       Impact factor: 3.894

2.  A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma.

Authors:  M Nagar; A Ogunyomade; D P S O'Brart; F Howes; J Marshall
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 3.  Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty.

Authors:  Joshua D Stein; Pratap Challa
Journal:  Curr Opin Ophthalmol       Date:  2007-03       Impact factor: 3.761

4.  Trials and tribulations of non-inferiority: the ximelagatran experience.

Authors:  Sanjay Kaul; George A Diamond; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

5.  Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork.

Authors:  D E Parshley; J M Bradley; J R Samples; E M Van Buskirk; T S Acott
Journal:  Curr Eye Res       Date:  1995-07       Impact factor: 2.424

6.  Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?

Authors:  Amy M Bovell; Karim F Damji; William G Hodge; William J Rock; Ralf R Buhrmann; Yi I Pan
Journal:  Can J Ophthalmol       Date:  2011-08-04       Impact factor: 1.882

7.  Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma.

Authors:  Mark S Juzych; Vikás Chopra; Michael R Banitt; Bret A Hughes; Chaesik Kim; Mark T Goulas; Dong H Shin
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

Review 8.  Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma.

Authors:  Hao Wang; Jin-Wei Cheng; Rui-Li Wei; Ji-Ping Cai; You Li; Xiao-Ye Ma
Journal:  Can J Ophthalmol       Date:  2013-06       Impact factor: 1.882

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

Review 10.  Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis.

Authors:  Wei Wang; Miao He; Minwen Zhou; Xiulan Zhang
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more
  5 in total

Review 1.  Selective laser trabeculoplasty: past, present, and future.

Authors:  A Garg; G Gazzard
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 2.  Laser trabeculoplasty for open-angle glaucoma and ocular hypertension.

Authors:  Christiane R Rolim-de-Moura; Augusto Paranhos; Mohamed Loutfi; David Burton; Richard Wormald; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2022-08-09

Review 3.  Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: An evidence-based review.

Authors:  Raul E Ruiz-Lozano; Jimena Alamillo-Velazquez; Gustavo Ortiz-Morales; Lucas A Garza-Garza; Manuel E Quiroga-Garza; Carlos Alvarez-Guzman; Alejandro Rodriguez-Garcia
Journal:  Int Ophthalmol       Date:  2022-08-13       Impact factor: 2.029

Review 4.  Energy Dose-Response in Selective Laser Trabeculoplasty: A Review.

Authors:  Nathan Radcliffe; Gus Gazzard; Thomas Samuelson; Peng Khaw; Xinghuai Sun; Tin Aung; Dennis Lam; Kuldev Singh; L Jay Katz; Michael Aronov; Zachary Sacks; Yoram Solberg; Richard Lindstrom; Michael Belkin
Journal:  J Glaucoma       Date:  2022-06-15       Impact factor: 2.290

5.  A Comparative Study of the Clinical Efficacy and Safety of Pneumatic Trabeculoplasty and Selective Laser Trabeculoplasty for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.

Authors:  Yanling Song; Qiujie Song; Yanhui Qin; Jinfeng Xu; Ping Chen; Hong Li; Wenjie Han
Journal:  Med Sci Monit       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.